Novel Immune Targets in Melanoma-Response

Jarem Edwards^{1

2

3

4}, Marcel Batten^{1

4}, Angela Ferguson^{2

3

4}, Umaimainthan Palendira^#^{2

3

4}, James S Wilmott^#^{1

2

4}, Georgina V Long^#^{1

2

4

5

6}, Richard A Scolyer^#^{7

2

4

8}

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
² Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
³ Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia.
⁴ Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
⁵ Mater Hospital, North Sydney, Australia.
⁶ Royal North Shore Hospital, Sydney, New South Wales, Australia.
⁷ Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia. Richard.Scolyer@melanoma.org.au.
⁸ Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

^# Contributed equally.

PMID: 31481485
DOI: 10.1158/1078-0432.CCR-19-1866

Comment

Novel Immune Targets in Melanoma-Response

Jarem Edwards et al. Clin Cancer Res. 2019.

. 2019 Sep 1;25(17):5424-5425.

doi: 10.1158/1078-0432.CCR-19-1866.

Authors

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
² Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
³ Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia.
⁴ Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
⁵ Mater Hospital, North Sydney, Australia.
⁶ Royal North Shore Hospital, Sydney, New South Wales, Australia.
⁷ Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia. Richard.Scolyer@melanoma.org.au.
⁸ Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

^# Contributed equally.

PMID: 31481485
DOI: 10.1158/1078-0432.CCR-19-1866

No abstract available

PubMed Disclaimer

Comment on

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.
Edwards J, Tasker A, Pires da Silva I, Quek C, Batten M, Ferguson A, Allen R, Allanson B, Saw RPM, Thompson JF, Menzies AM, Palendira U, Wilmott JS, Long GV, Scolyer RA. Edwards J, et al. Clin Cancer Res. 2019 Jun 1;25(11):3247-3258. doi: 10.1158/1078-0432.CCR-18-4011. Epub 2019 Feb 18. Clin Cancer Res. 2019. PMID: 30777877
Novel Immune Targets in Melanoma-Letter.
Nocentini G, Cari L, Riccardi C. Nocentini G, et al. Clin Cancer Res. 2019 Sep 1;25(17):5422-5423. doi: 10.1158/1078-0432.CCR-19-1140. Clin Cancer Res. 2019. PMID: 31481484 No abstract available.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Novel Immune Targets in Melanoma-Response

Affiliations

Novel Immune Targets in Melanoma-Response

Authors

Affiliations

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical